Stanford Study Traces Mechanism Behind Rare COVID Vaccine-Linked Heart Inflammation

A rare side effect that has been discussed since the early days of the COVID-19 vaccine rollout now has a proposed explanation. Researchers at Stanford, working with The Ohio State University, report that two immune proteins appear to drive vaccine-related myocarditis, the inflammation of the heart muscle that has been most closely tied to young men. The findings were published in the journal Science Translational Medicine.

The numbers frame how uncommon the condition is. According to a Stanford press release, myocarditis occurs in about one in 140,000 people after the first dose and about one in 32,000 after the second. Among males 30 and younger, the figure rises to one in 16,750. Symptoms include chest pain, shortness of breath, fever and palpitations, and they can appear one to three days after vaccination. Elevated cardiac troponin in the blood is another marker, and it signals damage to the heart muscle.

Joseph Wu, MD, PhD, the study author who directs the Stanford Cardiovascular Institute and is a professor of medicine and radiology, stressed that most patients recover quickly and regain full heart function. He told Fox News Digital that it is not a heart attack in the traditional sense, because there is no blockage of blood vessels. When symptoms are mild and there is no structural damage, doctors simply observe patients to confirm they recover. In rare cases, Wu noted, severe inflammation can lead to hospitalization, critical illness or death.

To look for a cause, the team analyzed blood samples from vaccinated people, some who had developed myocarditis and some who had not. Those with myocarditis carried two proteins, CXCL10 and IFN-gamma, which are released by immune cells and in turn trigger more inflammation. Wu said the team believes these two are the major drivers. The body needs such cytokines to fight viruses, he said, but they can become toxic in large amounts. In mouse and heart tissue models, high levels produced signs of heart irritation resembling mild myocarditis.

The more promising result came when the researchers blocked the two proteins. Wu described heart damage in the models falling substantially, without shutting down the immune response the vaccine is meant to produce. He suggested a targeted, fine-tuning approach might protect the heart, and that it could one day help prevent or treat myocarditis in people at highest risk while preserving the benefits of vaccination. The team also found that genistein, an estrogen-like compound found in soybeans, reduced inflammation in laboratory tests. It has not been tested in humans.

The caveats are significant, and Wu stated them plainly. Most of the data came from experimental systems, mice and human cells in the lab, which cannot fully capture how myocarditis develops and resolves in real patients. The work is preclinical, he said, so it does not change what people should do now, and clinical studies will be needed to show whether targeted treatments are safe and effective.

On risk, Wu said COVID infection is about 10 times more likely to cause myocarditis than mRNA vaccines. Fox News senior medical analyst Dr. Marc Siegel called the study very complex and said the immune mechanism makes sense. He added that myocarditis is worse with COVID, being more common and generally more severe. Wu said the overall benefits of vaccination still clearly outweigh the small risk for nearly all groups, and that mRNA vaccines remain a crucial tool.

Wu also suggested that other vaccines can cause myocarditis and inflammatory problems, though with more diffuse symptoms. Because mRNA COVID vaccines have drawn intense public scrutiny, he said, chest pain prompts a hospital visit and a troponin test, while achy muscles after a flu shot get brushed off. The study was funded by the National Institutes of Health and the Gootter-Jensen Foundation. The next step is clinical research in people.